fig2

Figure 2. Metabolic mechanisms of resistance to endocrine therapies: the androgen receptor (AR) and lipid metabolism crosstalk. A: overview of lipid metabolism changes mediating resistance to androgen deprivation therapy (ADT) and androgen receptor signaling inhibitors (ARSI); B: schematic representation of AR signaling and lipid metabolism crosstalk. Drug targeting fatty acid (FA) synthesis and FA oxidation (FAO) are indicated as potential non-canonical approaches to inhibit AR signaling in mCRPC. CPT1: carnitine palmitoyltransferase 1; FASN: fatty acid synthase; SREBPs: sterol regulatory-element binding proteins